A comprehensive view of Combination Therapy. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Pfizer reports combination COVID-19 booster based on original vaccine with omicron-specific protection and omicron-specific booster vaccine both increase omicron-fighting antibodies in tests; omicron-specific booster had strongest response against omicron

US health authorities debate whether to use modified vaccines for fall COVID-19 booster shots, with bivalent combination shots of original vaccine plus omicron protection top candidates; about 50% in US have never received first dose of vaccine

Pfizer partners with MorphoSys, Incyte to evaluate combined therapy to treat diffuse large B-cell lymphoma, a type of blood cancer; drugs include Pfizer’s experimental TTI-622, Morphosys and Incyte’s Monjuvi tafasitamab-cxix, Revlimid lenalidomide

FDA approves Amgen’s injectable Riabni rituximab-arrx, a biosimilar of Rituxan rituximab, to treat moderate to severe rheumatoid arthritis in adults; drug is used in combination with methotrexate

FDA approves Bristol Myers’ Opdivo nivolumab injectable used with chemotherapy and Opdivo plus Yervoy ipilimumab to treat advanced, metastatic esophageal squamous cell carcinoma; 20,640 new cases of esophageal cancer are diagnosed in US annually

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count